TRDA Entrada Therapeutics, Inc.
Price Chart
Executive Summary
Two top executives at Entrada Therapeutics sold a combined $629K in open-market sales over a 7-day window, with President & COO Dowden also exercising and immediately selling derivative shares. The total sales represent ~0.11% of market cap, a modest but notable cluster involving both the COO and R&D President, suggesting insider caution ahead of potential catalysts or data readouts.
Key Financial Metrics
Actionable Insight
Two top executives selling in the same window, with one exercising and immediately flipping options, is a cautionary signal. Monitor for upcoming clinical data readouts, earnings, or corporate events that may have prompted the selling. The stock has rallied strongly (T+5 +5.4%, T+20 +13.5% on prior neutral reports), so this cluster may indicate insiders taking profits near recent highs.
Key Facts
- President & COO Nathan Dowden sold 15,000 shares at $15.33 for $230K on May 4, 2026
- President of R&D Sethuraman Natarajan sold 25,907 shares at $15.39 for $399K on May 4, 2026
- Dowden also exercised 15,000 derivative shares at $1.74 ($26,100 cost) and immediately sold them
- Total open-market sales: $629K, representing ~0.11% of $563M market cap
- Cluster occurred in a 7-day window ending May 4, 2026
- No insider purchases were reported in this cluster
Financial Impact
Total insider sales of $629K, ~0.11% of market cap
Risk Factors
- Insider selling by both COO and R&D President may signal lack of near-term catalysts or concerns about upcoming data
- Derivative exercise and immediate sale suggests monetization rather than conviction holding
- Stock has appreciated significantly in recent months, increasing risk of mean reversion
Market Snapshot
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-TRDA-1777937131163 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 10, 2026
4d ago
|
8-K
| $5.96 awaiting T+1 | awaiting T+1 | — | $6.46 (+8.39%) |
|
Jun 2, 2026
12d ago
|
Press Release
| $6.64 $6.58 | ▼ −0.90% | ▼ −0.18% | $6.46 (−2.71%) |
|
May 7, 2026
5w ago
|
Press Release
| $6.85 $6.84 | ▼ −0.15% | ▼ −0.98% | $6.46 (−5.69%) |
|
May 4, 2026
5w ago
|
144
| $15.75 $16.03 | ▲ +1.78% | ▲ +0.39% | $6.46 (−58.98%) |
|
May 4, 2026
6w ago
|
Insider Cluster
| $15.79 $15.75 | ▲ +0.25% | ▲ +1.05% | $6.46 (+59.09%) |
|
Apr 24, 2026
7w ago
|
DEFA14A
| $12.63 $12.96 | ▲ +2.61% | ▲ +2.45% | $6.46 (−48.85%) |
|
Mar 4, 2026
14w ago
|
Insider Cluster
| $12.50 $11.62 | ▼ −7.04% | ▼ −6.47% | $6.46 (−48.32%) |
|
Feb 26, 2026
15w ago
|
8-K
| $12.79 $11.93 | ▲ +6.72% | ▲ +6.27% | $6.46 (+49.49%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access